ABP 215

DRUG2 trials

Sponsors

Amgen

Conditions

Metastatic Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung Cancer MetastaticNon-squamous NSCLC

Phase 3

Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

CompletedNCT01966003

AmgenNon-small Cell Lung Cancer Metastatic

Start: 2013-11-11End: 2015-07-23Updated: 2017-10-19

A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

WithdrawnNCT04466917

AmgenMetastatic Non-small Cell Lung Cancer (NSCLC), Non-squamous NSCLC

Start: 2021-05-15End: 2022-11-13Updated: 2023-07-03

Related Papers

Totality of evidence in development of the bevacizumab biosimilar ABP 215: Central and investigator evaluation of efficacy from the MAPLE study.

Journal of Clinical Oncology2019-05-201 citations

Clinical comparison of ABP 215 and bevacizumab in patients with NSCLC: Pharmacokinetic results and justification for extrapolation across bevacizumab indications.

Journal of Clinical Oncology2017-05-202 citations

Randomized, double-blind, phase 3 study evaluating efficacy and safety of ABP 215 compared with bevacizumab in patients with non-squamous NSCLC.

Journal of Clinical Oncology2016-05-2015 citations